Literature DB >> 10772643

Use of preferentially replicating bacteria for the treatment of cancer.

M Sznol1, S L Lin, D Bermudes, L M Zheng, I King.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10772643      PMCID： PMC300839          DOI： 10.1172/JCI9818

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  14 in total

1.  ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER.

Authors:  K ENGELBART; D GERICKE
Journal:  Cancer Res       Date:  1964-02       Impact factor: 12.701

2.  ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.

Authors:  E H THIELE; R N ARISON; G E BOXER
Journal:  Cancer Res       Date:  1964-02       Impact factor: 12.701

3.  ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA.

Authors:  J R MOESE; G MOESE
Journal:  Cancer Res       Date:  1964-02       Impact factor: 12.701

4.  Tumor-targeted Salmonella as a novel anticancer vector.

Authors:  J M Pawelek; K B Low; D Bermudes
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

5.  Escherichia coli msbB gene as a virulence factor and a therapeutic target.

Authors:  J E Somerville; L Cassiano; R P Darveau
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

6.  Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.

Authors:  M E Fox; M J Lemmon; M L Mauchline; T O Davis; A J Giaccia; N P Minton; J M Brown
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

7.  Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.

Authors:  M J Lemmon; P van Zijl; M E Fox; M L Mauchline; A J Giaccia; N P Minton; J M Brown
Journal:  Gene Ther       Date:  1997-08       Impact factor: 5.250

8.  Regulation of the proinflammatory effects of Fas ligand (CD95L).

Authors:  J J Chen; Y Sun; G J Nabel
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

9.  The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.

Authors:  L Thorsteinsson; G M O'Dowd; P M Harrington; P M Johnson
Journal:  APMIS       Date:  1998-09       Impact factor: 3.205

10.  Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo.

Authors:  K B Low; M Ittensohn; T Le; J Platt; S Sodi; M Amoss; O Ash; E Carmichael; A Chakraborty; J Fischer; S L Lin; X Luo; S I Miller; L Zheng; I King; J M Pawelek; D Bermudes
Journal:  Nat Biotechnol       Date:  1999-01       Impact factor: 54.908
View more
  45 in total

Review 1.  Microorganisms and cancer: quest for a therapy.

Authors:  A M Chakrabarty
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

2.  Effects of some natural immunomodulatory compounds in combination with thalidomide on survival rate and tumor size in fibrosarcoma-bearing mice.

Authors:  Reza Aghebati Maleki; Dariush Shanehbandi; Saeed Sadigh Eteghad; Habib Zarredar; Fatemeh Zare Shahneh; Leili Aghebati Maleki; Mehrnosh Samavati; Hamed Asadi; Seyed Ehsan Mosavi; Afshin Habibzadeh; Mozhdeh Mohammadian; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-25

3.  Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.

Authors:  Madiha Derouazi; Yan Wang; Raphaël Marlu; Olivier Epaulard; Jean-François Mayol; Nicolas Pasqual; Audrey Le Gouellec; Benoit Polack; Bertrand Toussaint
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

4.  Phagosome proteomics: a powerful tool to assess bacteria-mediated immunomodulation.

Authors:  Qingbo Li
Journal:  Bioeng Bugs       Date:  2011-07-01

Review 5.  The potential roles of bacteria to improve radiation treatment outcome.

Authors:  E Kouhsari; A Ghadimi-Daresajini; H Abdollahi; N Amirmozafari; S R Mahdavi; S Abbasian; S H Mousavi; H F Yaseri; M Moghaderi
Journal:  Clin Transl Oncol       Date:  2017-06-16       Impact factor: 3.405

Review 6.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

7.  Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli.

Authors:  Jung-Joon Min; Hyun-Ju Kim; Jae Hyo Park; Sungmin Moon; Jae Ho Jeong; Yeoung-Jin Hong; Kyoung-Oh Cho; Jong Hee Nam; Nacksung Kim; Young-Kyu Park; Hee-Seung Bom; Joon Haeng Rhee; Hyon E Choy
Journal:  Mol Imaging Biol       Date:  2007-11-10       Impact factor: 3.488

8.  A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Authors:  Zhiyu Li; John Fallon; John Mandeli; James Wetmur; Savio L C Woo
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 13.506

9.  Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer.

Authors:  Clinton Yam; Ming Zhao; Katsuhiro Hayashi; Huaiyu Ma; Hiroyuki Kishimoto; Michele McElroy; Michael Bouvet; Robert M Hoffman
Journal:  J Surg Res       Date:  2009-03-31       Impact factor: 2.192

10.  Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium.

Authors:  H Kimura; L Zhang; M Zhao; K Hayashi; H Tsuchiya; K Tomita; M Bouvet; J Wessels; R M Hoffman
Journal:  Cell Prolif       Date:  2009-11-18       Impact factor: 6.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.